Anne M Fitzpatrick1, Leonard B Bacharier2, Theresa W Guilbert3, Daniel J Jackson4, Stanley J Szefler5, Avraham Beigelman2, Michael D Cabana6, Ronina Covar7, Fernando Holguin8, Robert F Lemanske4, Fernando D Martinez9, Wayne Morgan9, Wanda Phipatanakul10, Jacqueline A Pongracic11, Robert S Zeiger12, David T Mauger13. 1. Department of Pediatrics, Emory University, Atlanta, Ga; Children's Healthcare of Atlanta, Atlanta, Ga. Electronic address: anne.fitzpatrick@emory.edu. 2. Department of Pediatrics, Washington University, St. Louis, Mo. 3. Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio. 4. Department of Pediatrics, University of Wisconsin, Madison, Wis. 5. Children's Hospital Colorado, Aurora, Colo; Department of Pediatrics, University of Colorado, Aurora, Colo. 6. Department of Pediatrics, University of California San Francisco, San Francisco, Calif. 7. Department of Pediatrics, National Jewish Health, Denver, Colo. 8. Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pa. 9. Department of Pediatrics, University of Arizona, Tucson, Ariz. 10. Boston Children's Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass. 11. Children's Memorial Hospital, Chicago, Ill. 12. Kaiser Permanente, Southern California Region, San Diego, Calif; Department of Pediatrics, University of California San Diego, San Diego, Calif. 13. Department of Statistics, Pennsylvania State University, Hershey, Pa.
Abstract
BACKGROUND: Recurrent preschool wheezing is a heterogeneous disorder with significant morbidity, yet little is known about phenotypic determinants and their impact on clinical outcomes. OBJECTIVE: Latent class analysis (LCA) was used to identify latent classes of recurrent preschool wheeze and their association with future exacerbations and inhaled corticosteroid (ICS) treatment response. METHODS: Data from 5 clinical trials of 1708 children aged 12 to 71 months with recurrent wheezing were merged. LCA was performed on 10 demographic, exposure, and sensitization variables to determine the optimal number of latent classes. The primary outcome was the annualized rate of wheezing exacerbations requiring systemic corticosteroids during the study intervention period; the secondary outcome was the time to first exacerbation. Exploratory analyses examined the effect of daily ICS treatment on exacerbation outcomes. RESULTS: Four latent classes of recurrent wheezing were identified; these were not distinguished by current symptoms or historical exacerbations but differed with regard to allergen sensitization and/or exposures. Annualized exacerbation rates (mean ± SEM/year) were 0.65 ± 0.06 for class 1 ("minimal sensitization"), 0.93 ± 0.10 for class 2 ("sensitization with indoor pet exposure"), 0.60 ± 0.07 for class 3 ("sensitization with tobacco smoke exposure"), and 0.81 ± 0.10 for class 4 ("multiple sensitization and eczema") (P < .001). In a research setting of high adherence, daily ICS treatment improved exacerbation rates in classes 2 and 4 but not the other groups. CONCLUSIONS: Sensitization and exposure assessments are useful in the prediction of future exacerbation and may identify children most likely to respond favorably to daily ICS treatment.
BACKGROUND: Recurrent preschool wheezing is a heterogeneous disorder with significant morbidity, yet little is known about phenotypic determinants and their impact on clinical outcomes. OBJECTIVE: Latent class analysis (LCA) was used to identify latent classes of recurrent preschool wheeze and their association with future exacerbations and inhaled corticosteroid (ICS) treatment response. METHODS: Data from 5 clinical trials of 1708 children aged 12 to 71 months with recurrent wheezing were merged. LCA was performed on 10 demographic, exposure, and sensitization variables to determine the optimal number of latent classes. The primary outcome was the annualized rate of wheezing exacerbations requiring systemic corticosteroids during the study intervention period; the secondary outcome was the time to first exacerbation. Exploratory analyses examined the effect of daily ICS treatment on exacerbation outcomes. RESULTS: Four latent classes of recurrent wheezing were identified; these were not distinguished by current symptoms or historical exacerbations but differed with regard to allergen sensitization and/or exposures. Annualized exacerbation rates (mean ± SEM/year) were 0.65 ± 0.06 for class 1 ("minimal sensitization"), 0.93 ± 0.10 for class 2 ("sensitization with indoor pet exposure"), 0.60 ± 0.07 for class 3 ("sensitization with tobacco smoke exposure"), and 0.81 ± 0.10 for class 4 ("multiple sensitization and eczema") (P < .001). In a research setting of high adherence, daily ICS treatment improved exacerbation rates in classes 2 and 4 but not the other groups. CONCLUSIONS: Sensitization and exposure assessments are useful in the prediction of future exacerbation and may identify children most likely to respond favorably to daily ICS treatment.
Authors: Theresa W Guilbert; Wayne J Morgan; Marzena Krawiec; Robert F Lemanske; Chris Sorkness; Stanley J Szefler; Gary Larsen; Joseph D Spahn; Robert S Zeiger; Gregory Heldt; Robert C Strunk; Leonard B Bacharier; Gordon R Bloomberg; Vernon M Chinchilli; Susan J Boehmer; Elizabeth A Mauger; David T Mauger; Lynn M Taussig; Fernando D Martinez Journal: Control Clin Trials Date: 2004-06
Authors: Theresa W Guilbert; Wayne J Morgan; Robert S Zeiger; David T Mauger; Susan J Boehmer; Stanley J Szefler; Leonard B Bacharier; Robert F Lemanske; Robert C Strunk; David B Allen; Gordon R Bloomberg; Gregory Heldt; Marzena Krawiec; Gary Larsen; Andrew H Liu; Vernon M Chinchilli; Christine A Sorkness; Lynn M Taussig; Fernando D Martinez Journal: N Engl J Med Date: 2006-05-11 Impact factor: 91.245
Authors: Christine A Sorkness; Robert F Lemanske; David T Mauger; Susan J Boehmer; Vernon M Chinchilli; Fernando D Martinez; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Leonard B Bacharier; Gordon R Bloomberg; Ronina A Covar; Theresa W Guilbert; Gregory Heldt; Gary Larsen; Michael H Mellon; Wayne J Morgan; Mark H Moss; Joseph D Spahn; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2006-11-30 Impact factor: 10.793
Authors: R T Stein; C J Holberg; D Sherrill; A L Wright; W J Morgan; L Taussig; F D Martinez Journal: Am J Epidemiol Date: 1999-06-01 Impact factor: 4.897
Authors: Leonard B Bacharier; Brenda R Phillips; Gordon R Bloomberg; Robert S Zeiger; Ian M Paul; Marzena Krawiec; Theresa Guilbert; Vernon M Chinchilli; Robert C Strunk Journal: J Allergy Clin Immunol Date: 2007-03 Impact factor: 10.793
Authors: Stanley J Szefler; Brenda R Phillips; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Robert S Zeiger; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2005-02 Impact factor: 10.793
Authors: Theresa W Guilbert; Wayne J Morgan; Robert S Zeiger; Leonard B Bacharier; Susan J Boehmer; Marzena Krawiec; Gary Larsen; Robert F Lemanske; Andrew Liu; David T Mauger; Chris Sorkness; Stanley J Szefler; Robert C Strunk; Lynn M Taussig; Fernando D Martinez Journal: J Allergy Clin Immunol Date: 2004-12 Impact factor: 10.793
Authors: Sheel N Shah; Jocelyn R Grunwell; Ahmad F Mohammad; Susan T Stephenson; Gerald B Lee; Brian P Vickery; Anne M Fitzpatrick Journal: J Allergy Clin Immunol Pract Date: 2021-03-27
Authors: Dong In Suh; Mi-Jin Kang; Yoon Mee Park; Jun-Kyu Lee; So-Yeon Lee; Youn Ho Sheen; Kyung Won Kim; Kangmo Ahn; Soo-Jong Hong Journal: Asia Pac Allergy Date: 2019-10-14
Authors: Helena Donath; Sven Kluge; Georgia Sideri; Jordis Trischler; Silivija P Jerkic; Johannes Schulze; Stefan Zielen; Katharina Blumchen Journal: Front Pediatr Date: 2020-11-20 Impact factor: 3.418
Authors: Rebecca L Watkinson; Kevin Looi; Ingrid A Laing; Antonella Cianferoni; Anthony Kicic Journal: Front Immunol Date: 2021-11-29 Impact factor: 7.561
Authors: Pablo Rodriguez Del Rio; Andrew H Liu; Magnus P Borres; Eva Södergren; Fabio Iachetti; Thomas B Casale Journal: Int J Mol Sci Date: 2022-03-31 Impact factor: 5.923